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Supplementary Figure 1: Pearson correlations between the 10 graph metrics used as input in the neural 
network. The color-scale represents r-values; stronger positive correlations being represented by lighter 
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Supplementary Fig. 2 
 
 
Supplementary Figure 2. Age prediction from support vector machine models using original 
graph metrics as input (A) and age prediction from support vector machine models using 




Supplementary Table 1. Percentage of frames retained from resting-state fMRI scans in each 
cohort 
 
Cohort Average % frames retained ± SD 
CamCAN 86.2 ± 15.5 
FCP-Cambridge 100 ± 0 
DIAN 93.8 ± 12.0 
Prevent-AD 85.0 ± 17.2 
ADNI 80.7 ± 15.4 
ICBM 96.76 ± 8.0 





Supplementary Table 2. Functional brain parcellation (based on Power and Petersen 
functional atlas)
 
  MNI space  Suggested System 
ROI  X Y Z   
13  -7 -52 61  Sensory/somatomotor Hand 
14  -14 -18 40  Sensory/somatomotor Hand 
15  0,1 -15 47  Sensory/somatomotor Hand 
16  9,5 -2 45  Sensory/somatomotor Hand 
17  -7 -21 65  Sensory/somatomotor Hand 
18  -7 -33 72  Sensory/somatomotor Hand 
19  13 -33 75  Sensory/somatomotor Hand 
20  -54 -23 43  Sensory/somatomotor Hand 
21  29 -17 71  Sensory/somatomotor Hand 
22  9,9 -46 73  Sensory/somatomotor Hand 
23  -23 -30 72  Sensory/somatomotor Hand 
24  -40 -19 54  Sensory/somatomotor Hand 
25  29 -39 59  Sensory/somatomotor Hand 
26  50 -20 42  Sensory/somatomotor Hand 
27  -38 -27 69  Sensory/somatomotor Hand 
28  20 -29 60  Sensory/somatomotor Hand 
29  44 -8 57  Sensory/somatomotor Hand 
30  -29 -43 61  Sensory/somatomotor Hand 
31  10 -17 74  Sensory/somatomotor Hand 
32  22 -42 69  Sensory/somatomotor Hand 
33  -45 -32 47  Sensory/somatomotor Hand 
34  -21 -31 61  Sensory/somatomotor Hand 
35  -13 -17 75  Sensory/somatomotor Hand 
36  42 -20 55  Sensory/somatomotor Hand 
37  -38 -15 69  Sensory/somatomotor Hand 
38  -16 -46 73  Sensory/somatomotor Hand 
39  2,4 -28 60  Sensory/somatomotor Hand 
40  3,5 -17 58  Sensory/somatomotor Hand 
41  38 -17 45  Sensory/somatomotor Hand 
42  -49 -11 35  Sensory/somatomotor Mouth 
43  36 -9 14  Sensory/somatomotor Mouth 
44  51 -6 32  Sensory/somatomotor Mouth 
45  -53 -10 24  Sensory/somatomotor Mouth 
46  66 -8 25  Sensory/somatomotor Mouth 
47  -3 2,4 53  Cingulo-opercular Task Control 
48  54 -28 34  Cingulo-opercular Task Control 
49  19 -8 64  Cingulo-opercular Task Control 
50  -16 -5 71  Cingulo-opercular Task Control 
51  -10 -2 42  Cingulo-opercular Task Control 
52  37 0,8 -4  Cingulo-opercular Task Control 
53  13 -1 70  Cingulo-opercular Task Control 
54  6,5 7,7 51  Cingulo-opercular Task Control 
55  -45 0,1 8,8  Cingulo-opercular Task Control 
56  49 8,3 -1  Cingulo-opercular Task Control 
57  -34 3,3 4,2  Cingulo-opercular Task Control 
58  -51 8,3 -2  Cingulo-opercular Task Control 
59  -5 18 34  Cingulo-opercular Task Control 
60  36 10 1,2  Cingulo-opercular Task Control 
61  32 -26 13  Auditory 
62  65 -33 20  Auditory 
63  58 -16 7,5  Auditory 
64  -38 -33 17  Auditory 
65  -60 -25 14  Auditory 
66  -49 -26 5,2  Auditory 
67  43 -23 20  Auditory 
68  -50 -34 26  Auditory 
69  -53 -22 23  Auditory 
70  -55 -9 12  Auditory 
71  56 -5 13  Auditory 
72  59 -17 29  Auditory 
73  -30 -27 12  Auditory 
 
 
  MNI space  Suggested System 
ROI  X Y Z   
74  -41 -75 26  Default mode 
75  5,6 67 -4  Default mode 
76  8,4 48 -15  Default mode 
77  -13 -40 0,9  Default mode 
78  -18 63 -9  Default mode 
79  -46 -61 21  Default mode 
80  43 -72 28  Default mode 
81  -44 12 -34  Default mode 
82  46 16 -30  Default mode 
86  -44 -65 35  Default mode 
87  -39 -75 44  Default mode 
88  -7 -55 27  Default mode 
89  5,9 -59 35  Default mode 
90  -11 -56 16  Default mode 
91  -3 -49 13  Default mode 
92  7,9 -48 31  Default mode 
93  15 -63 26  Default mode 
94  -2 -37 44  Default mode 
95  11 -54 17  Default mode 
96  52 -59 36  Default mode 
97  23 33 48  Default mode 
98  -10 39 52  Default mode 
99  -16 29 53  Default mode 
100  -35 20 51  Default mode 
101  22 39 39  Default mode 
102  13 55 38  Default mode 
103  -10 55 39  Default mode 
104  -20 45 39  Default mode 
105  5,9 54 16  Default mode 
106  6,1 64 22  Default mode 
107  -7 51 -1  Default mode 
108  8,8 54 3,5  Default mode 
109  -3 44 -9  Default mode 
110  7,5 42 -5  Default mode 
111  -11 45 7,6  Default mode 
112  -2 38 36  Default mode 
113  -3 42 16  Default mode 
114  -20 64 19  Default mode 
115  -8 48 23  Default mode 
117  -56 -13 -10  Default mode 
118  -58 -30 -4  Default mode 
119  65 -31 -9  Default mode 
120  -68 -41 -5  Default mode 
121  13 30 59  Default mode 
122  12 36 20  Default mode 
123  52 -2 -16  Default mode 
124  -26 -40 -8  Default mode 
125  27 -37 -13  Default mode 
126  -34 -38 -16  Default mode 
127  28 -77 -32  Default mode 
128  52 6,8 -30  Default mode 
129  -53 2,6 -27  Default mode 
130  47 -50 29  Default mode 
131  -49 -42 0,8  Default mode 
133  -2 -35 31  Memory retrieval 
134  -7 -71 42  Memory retrieval 
135  11 -66 42  Memory retrieval 
136  4,2 -48 51  Memory retrieval 
137  -46 31 -13  Default mode 
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138  -10 11 67  Ventral attention 
139  49 35 -12  Default mode 
       
 
  MNI space  Suggested System 
ROI  X Y Z   
143  18 -47 -10  Visual 
144  40 -72 14  Visual 
145  8,5 -72 11  Visual 
146  -8 -81 7,4  Visual 
147  -28 -79 19  Visual 
148  20 -66 1,7  Visual 
149  -24 -91 19  Visual 
150  27 -59 -9  Visual 
151  -15 -72 -8  Visual 
152  -18 -68 4,8  Visual 
153  43 -78 -12  Visual 
154  -47 -76 -10  Visual 
155  -14 -91 31  Visual 
156  15 -87 37  Visual 
157  29 -77 25  Visual 
158  20 -86 -2  Visual 
159  15 -77 31  Visual 
160  -16 -52 -1  Visual 
161  42 -66 -8  Visual 
162  24 -87 24  Visual 
163  5,6 -72 24  Visual 
164  -42 -74 0,4  Visual 
165  26 -79 -16  Visual 
166  -16 -77 34  Visual 
167  -3 -81 21  Visual 
168  -40 -88 -6  Visual 
169  37 -84 13  Visual 
170  6,2 -81 6,1  Visual 
171  -26 -90 3,1  Visual 
172  -33 -79 -13  Visual 
173  37 -81 1,2  Visual 
174  -44 1,8 46  Fronto-parietal Task Control 
175  48 25 27  Fronto-parietal Task Control 
176  -47 11 23  Fronto-parietal Task Control 
177  -53 -49 43  Fronto-parietal Task Control 
178  -23 11 64  Fronto-parietal Task Control 
179  58 -53 -14  Fronto-parietal Task Control 
180  24 45 -15  Fronto-parietal Task Control 
181  34 54 -13  Fronto-parietal Task Control 
186  47 9,9 33  Fronto-parietal Task Control 
187  -41 5,8 33  Fronto-parietal Task Control 
188  -42 38 21  Fronto-parietal Task Control 
189  38 43 15  Fronto-parietal Task Control 
190  49 -42 45  Fronto-parietal Task Control 
191  -28 -58 48  Fronto-parietal Task Control 
192  44 -53 47  Fronto-parietal Task Control 
193  32 14 56  Fronto-parietal Task Control 
194  37 -65 40  Fronto-parietal Task Control 
195  -42 -55 45  Fronto-parietal Task Control 
196  40 18 40  Fronto-parietal Task Control 
197  -34 55 4,4  Fronto-parietal Task Control 
198  -42 45 -2  Fronto-parietal Task Control 
199  33 -53 44  Fronto-parietal Task Control 
200  43 49 -2  Fronto-parietal Task Control 
201  -42 25 30  Fronto-parietal Task Control 
202  -3 26 44  Fronto-parietal Task Control 
203  11 -39 50  Salience 
204  55 -45 37  Salience 
205  42 -0 47  Salience 
206  31 33 26  Salience 
207  48 22 9,7  Salience 
208  -35 20 0,1  Salience 
209  36 22 2,6  Salience 




  MNI space  Suggested System 
ROI  X Y Z   
211  34 16 -8  Salience 
212  -11 26 25  Salience 
213  -1 15 44  Salience 
214  -28 52 21  Salience 
215  -0 30 27  Salience 
216  5,2 23 37  Salience 
217  10 22 27  Salience 
218  31 56 14  Salience 
219  26 50 27  Salience 
220  -39 51 17  Salience 
221  1,8 -24 30  Memory retrieval 
222  6,3 -24 -0  Subcortical 
223  -2 -13 12  Subcortical 
224  -10 -18 7  Subcortical 
225  12 -17 7,5  Subcortical 
226  -5 -28 -4  Subcortical 
227  -22 7,5 -5  Subcortical 
228  -15 3,6 8  Subcortical 
229  31 -14 1,7  Subcortical 
230  23 10 1,5  Subcortical 
231  29 0,8 4  Subcortical 
232  -31 -11 -0  Subcortical 
233  15 4,9 7,2  Subcortical 
234  8,6 -4 5,8  Subcortical 
235  54 -43 22  Ventral attention 
236  -56 -50 9,9  Ventral attention 
237  -55 -40 14  Ventral attention 
238  52 -33 7,6  Ventral attention 
239  51 -29 -4  Ventral attention 
240  56 -46 11  Ventral attention 
241  53 33 0,6  Ventral attention 
242  -49 25 -1  Ventral attention 
251  9,6 -62 61  Dorsal attention 
252  -52 -63 5,3  Dorsal attention 
255  47 -30 49  Sensory/somatomotor Hand 
256  22 -65 48  Dorsal attention 
257  46 -59 3,9  Dorsal attention 
258  25 -58 60  Dorsal attention 
259  -33 -46 47  Dorsal attention 
260  -27 -71 37  Dorsal attention 
261  -32 -1 54  Dorsal attention 
262  -42 -60 -9  Dorsal attention 
263  -17 -59 64  Dorsal attention 
264  29 -5 54  Dorsal attention 
265  -10 14 -2  Limbic 
266  10 14 -2  Limbic 
267  -22 -2 -22  Limbic 
268  26 -2 -22  Limbic 
269  -24 -14 -18  Limbic 
270  26 -14 -18  Limbic 
271  -28 -34 -6  Limbic 










Supplementary Table 3: Gene primers in DIAN 
Gene Ensembl_Transcript_ID Exon Direction Sequence 
PSEN2 ENST00000366783.3 4 Forward GACAGGCATCTCTTGGAAGC 
  4 Reverse CATCAGGGAATGAATGTCTGG 
  5 Forward ACTTCTCATTTCTGGTTCCA 
  5 Reverse TAGGTCACAATCCAGGAGG 
  6 Forward ACTCCATCAGGGCAGCAT 
  6 Reverse AAAAATCTGGGTCTATTTTCCTCT  
  8 Forward GTTGGGACTGAATGGTGGTA 
  8 Reverse CCCTCTGTTTTACAAAGGCG 
PSEN1 ENST00000324501.5 4 Forward AACTCATAGTGACGGGTCTG  
  4 Reverse GTAATAACCCCTCGCTCTCT  
  5 Forward TTGGTGAGTTGGGGAAA 
  5 Reverse CACAGTGAGGAGGAAGAAAA 
  6 Forward CGACAAAGTGAGACCCTGT 
  6 Reverse AGTACATGGCTTTAAATGATAGCT 
  7 Forward ATGTTTGGGAGCCATCA 
  7 Reverse CCAGCCGAAATCTTCAA 
  8 Forward TCACCTGCCATTTATTTCA 
  8 Reverse CAGGAATGCTGTGCATTTA 
  9 Forward CTGCTAAAACCAAAGAGAACC 
  9 Reverse TGTATTTACTGGGCATTATCATAG 
  11 Forward AAAACACAGCTGAAGCCTAA 
  11 Reverse GCTCCTCAGATAGCTGGAAT 
  12 Forward TCCAGATTGAATGAACGTCT 
  12 Reverse TGGAAGGAAGCTGCAAA 
APP ENST00000346798.3 7 Forward ATGCTGCCTAATAAACCAGTCC 
  7 Reverse TCCCAAGAACCAGGAAAATCAA 
  16 Forward GGTTTCCCTTACCCTTTCATTT 
  16 Reverse TCAGCCTAGCCTATTTATTTTCT 
  17 Forward TGAAACTTTTTATATAACCTCATCCAA  
  17 Reverse CATGGAAGCACACTGATTCG  









Supplementary Table 4: Gene primers in PREVENT-AD 
Gene Variant Analyses Sequence  
APOE rs429358 amplification forward 5’-ACGGCTGTCCAAGGAGCTG-3’ 
  amplification reverse biotinylated 5’-CACCTCGCCGCGGTACTG-3’ 
  sequencing 5’-CGGACATGGAGGACG-3’ 
 rs7412 amplification forward 5’-CTCCGCGATGCCGATGAC-3’ 
  amplification reverse biotinylated 5’-CCCCGGCCTGGTACACTG-3’ 







Race/ethnicity from the different cohorts 
DIAN: The sample mainly identified as non-Hispanic/White, both for mutation non-carriers 
(90% from the training set and 100% from the test set) and mutation carriers (80% from the 
test set).  
The ten remaining mutation non-carriers (all from the training set) identified as 
Hispanic/White (n=4), Hispanic with no further specification (n=2), non-Hispanic/Middle 
Eastern (n=1) or non-Hispanic/Aboriginal (n=2). Regarding the 24 mutation carriers with a 
different race/ethnicity, they identified themselves as Hispanic/White (n=10), Hispanic with 
no further specification (n=6), non-Hispanic/Middle Eastern-North Africa (n=2), Aboriginal 
(n=1), native Hawaiian or other pacific islanders (n=3), Hispanic/Black or African American 
(n=1) and non-Hispanic/Asian (n=1). 
 
PREVENT-AD: The sample was mainly White/Caucasian with the exception of 4 participants 
(2 Hispanics, 1 Haitian and 1 unspecified). 
 
ADNI: The sample mainly identified as non-Hispanic/White (83% of those included in the 
training set and 93% of those included in the test set), with the exception of 6 subjects (1 
Hispanic/White, 1 unknow ethnicity/White and 3 non-Hispanic/not White [1 Black, 1 with 
more than one race and 1 unknown] in the training set, and 1 Hispanic/White in the test set). 
 
FCP-Cambridge, CamCAN and ICBM: Participants from the FCP-Cambridge were recruited 
from the Cambridge (MA, USA) area, CamCAN is a population-based cohort recruited within 
the Cambridge City (UK) area (excluding term-time residents of colleges and universities) 
and the ICBM cohort was recruited in the Montreal (QC, Canada) area; however further 
demographic information, including specific information on race/ethnicity, was not provided 
for these cohorts. 
 
 
Estimated years to symptom onset  
 
Estimated expected years to symptom onset (EYO) was computed in the two cohorts by 
subtracting each participant’s age at assessment from his/her parent’s age at symptom onset. In 
DIAN, the parental age at onset was determined using semi-structured interview in which 
family members were asked about the age of first progressive cognitive decline.1 In PREVENT-
 10 
AD, EYO was calculated using the age of the parent at which the family observed significant 
cognitive/memory changes, as reported by the participant during the medical interview.2–4  
 
We conducted partial correlations between EYO and the predicted age difference (PAD), 
controlling for the influence of chronological age, in DIAN and PREVENT-AD.  
 
 
Calculation of small-worldness and resilience 
 
For a thresholded correlation matrix G, small-worldness was calculated as Supplementary 
Equation 1:  
 
small-worldness = [(clusteringG ⁄ clusteringrandom)  
⁄ (efficiencyrandom ⁄ efficiencyG)] 
(1) 
 
in which clustering is the clustering coefficient, and indicates the extent to which nodes are 
clustered together. The efficiency indicates the average of the inverse path length between 
nodes of the matrix. The subscript random indicates when these measures are taken on 
randomly scrambled matrices with preserved degree count for each node in G, and were 
generated using the function randmio_und. Random clustering coefficient and efficiency were 
averaged over 100 random matrices, generated for each scan. 
 
Resilience is a measure of the robustness of network G as node hubs are removed. Networks 
with scale-free properties (i.e. node degree probabilities follow a power-law distribution) are 
resilient to random attacks and can be described as Supplementary Equation 2: 
 
p(k) α k-y (2)
 
where p(k) is the probability of a node having a degree of k (or k total connections), and y is an 
exponent. On a log-log scale this probability distribution is linear, and thus resilience of G can 
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